Daiichi Buy Of India’s Ranbaxy Expected To Be Final By End Of Year
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's purchase of India's largest drug maker, Ranbaxy Laboratories, is expected to be completed by the end of the year. Ranbaxy CEO Malvinder Singh said he expected the $4.6 billion deal to be completed by then, enabling the generics maker to strengthen its Indian business. Singh told reporters that despite the U.S. allegations it misbranded or adulterated some of its drugs shipped to the United States, the company is getting back to strength there. "I am looking at strengthening India business…," he said. (Click here for more